GlassScriptPhysician profile
Panayotes Yannopoulos
NPI 1245323641
$14,633.04
in general payments reported to CMS, 2019-2025
39 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,997 · 2020: $1,724 · 2021: $2,569 · 2022: $2,939 · 2023: $1,515 · 2024: $1,751 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,341 · Education: $63.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,341.37 |
| Education | $63.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,580.56 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $2,199.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,307.25 | 2019-2025 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $1,064.86 | 2019-2023 | |
| Glaxosmithkline, LLC. | $903.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Abbvie INC. | $730.78 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $688.28 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Lilly USA, LLC | $602.43 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $506.08 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.39 | 2019-2025 | Xifaxan, Relistor |
| Janssen Pharmaceuticals, INC | $475.25 | 2019-2023 | Xarelto |
| Cequr Corporation | $328.87 | 2022-2023 | Cequr Simplicity |
| Exact Sciences Corporation | $320.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $274.54 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $244.83 | 2019-2023 | Veozah, Myrbetriq |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Panayotes Yannopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.